Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 15;20(10):2525-9.
doi: 10.1158/1078-0432.CCR-14-0511.

Pharmacologic biomarkers in the development of stratified cancer medicine

William Douglas Figg  1 , David R Newell  1
Affiliations

Pharmacologic biomarkers in the development of stratified cancer medicine

William Douglas Figg et al. Clin Cancer Res. .

Abstract

Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate how PD biomarkers can be powerful tools for guiding treatment strategies. We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine. See all articles in this CCR focus section, "Progress in pharmacodynamic endpoints."

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the processes determining drug disposition in the human body and the relationship of pharmacokinetics and pharmacodynamics to these processes. Reproduced from Beelen and Lewis (1) with kind permission from Springer Science + Business Media.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Beelen AP, Lewis LD. Clinical pharmacology overview. In: Figg WD, McLeod HL, editors. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Springer; New York: 2004. pp. 111–27.
    1. Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014;20:xx–xx. - PubMed
    1. Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations. Clin Cancer Res. 2014;20:xx–xx. - PMC - PubMed
    1. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res. 2014;20:xx–xx. - PubMed
    1. van der Veldt AAM, Lammertsma AA. In vivo imaging as a pharmacodynamic marker. Clin Cancer Res. 2014;20:xx–xx. - PubMed

Publication types

LinkOut - more resources